Another week, another takeover deal from AstraZeneca.
Last week AstraZeneca bought Amolyt Pharma for over $1 billion and today the FTSE 100-listed giant is paying over $2 billion for Fusion Pharmaceutical, a US-listed biopharmaceutical company...
There has been talk that perhaps dealmaking in the biopharmaceutical industry was waning following the the string of deal announcements in December 2023.
However, AstraZeneca has just put paid to that theory by announcing another takeover deal. This time the FTSE 100-listed company has agreed to purchase Amolyt Pharma, a France-based company focused on developing novel treatments for rare endocrine diseases...
Little old Betaville has noticed that three of the world's largest pharmaceutical giants have all recently done two major takeover deals within a few weeks, and in some cases days, of each other...
Dealmaking may be a bit lacklustre at the moment but if there is one sector that is seeing a lot of activity right now it's the biotechnology industry.
The latest deal to be announced is AstraZeneca's $1.1 acquisition of Icosavax, a US-listed developer of vaccines for respitory diseases...
The Sunday newspapers were given a "free" mega story when AstraZeneca announced its $40 billion takeover of US-based Alexion Pharmaceuticals on Saturday. So, naturally I thought they would all lead their respective business section front pages on the biggest pharma deal of the year carried out by a FTSE 100-listed company...
So...there was no statement from AstraZeneca this morning regarding Gilead.
And both the The Times and The Daily Telegraph appear to be poring cold water on the prospect of $200 billion plus merger, which was unveiled yesterday by Bloomberg. Below is the link to The Times report:..
There is a big story breaking on Bloomberg right now about AstraZeneca trying to buy Gilead to create a $200 billion pharmaceutical giant. Below is the link:..
So, the cat is finally out of the bag at Circassia Pharmaceuticals: the company announced this morning that it would cancel the agreement with AstraZeneca for the US commercial rights to Tudorza and Duaklir in return for the FTSE 100 giant writing off a $150 million loan...